The Greater Cannabis Company, Inc. (GCAN)
The Greater Cannabis Company, Inc. operates in the Medical - Pharmaceuticals industry of the Healthcare sector, headquartered in Baltimore, MD, US. The stock last traded at $0.23, down 17.82% on the session, giving a market capitalisation of $228,806. On trailing twelve-month figures it carries a trailing P/E of 2301.00, a net margin of 0.0%. Its beta of 0.34 implies it has historically moved less than the broad market.
The Greater Cannabis Company, Inc. engages in the development and commercialization of cannabinoid therapeutics. It offers an oral transmucosal patch platform, which provides loaded actives absorbed by the buccal mucosa into the body. The company has a license agreement with Shaare Zedek Scientific Ltd. that focuses on treatment of autism, schizophrenia, Parkinson’s disease, Alzheimer’s disease, and other neuropsychiatric disorders. The company was founded in 2014 and is based in Baltimore, Maryland.
The Greater Cannabis Company, Inc. is most often compared with the following Healthcare names: